Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 1,010 Shares of Stock

Key Points

• Natera insider Solomon Moshkevich sold 1,010 shares at an average price of $260.49, generating $263,094.90. The Rule 10b5-1 transaction covered tax withholding related to vested equity awards, leaving him with 133,633 shares.
• Moshkevich has made several additional Natera sales in recent months, including 1,204 shares on July 28 and 3,000 shares each in June and July.
• Natera shares recently traded at $253.82, while analysts maintain a “Moderate Buy” consensus with an average price target of $267.83; institutional investors own approximately 99.9% of the stock.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 1,010 shares of the company's stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $260.49, for a total value of $263,094.90. Following the sale, the insider directly owned 133,633 shares in the company, valued at approximately $34,810,060.17. This represents a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The stock was sold at an average price of $254.07, for a total transaction of $305,900.28.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $272.90, for a total transaction of $818,700.00.
• On Monday, June 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $218.43, for a total transaction of $655,290.00.
• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The stock was sold at an average price of $202.84, for a total transaction of $335,091.68.
• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45.

Natera Price Performance

Shares of NASDAQ:NTRA traded up $1.60 during trading on Wednesday, reaching $253.82. 925,147 shares of the company's stock traded hands, compared to its average volume of 1,091,572. The stock has a market capitalization of $36.35 billion, a P/E ratio of -155.72 and a beta of 1.51. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $288.04. The company has a 50 day moving average of $244.16 and a 200-day moving average of $221.65.

Analyst Ratings Changes

NTRA has been the topic of a number of research reports. Wolfe Research initiated coverage on Natera in a research report on Tuesday, June 2nd. They set an "outperform" rating and a $260.00 price target on the stock. BTIG Research set a $275.00 price objective on Natera and gave the company a "buy" rating in a research report on Wednesday, June 24th. Wells Fargo & Company upped their price objective on Natera from $215.00 to $220.00 and gave the stock an "equal weight" rating in a research note on Friday, May 8th. Canaccord Genuity Group raised their target price on Natera from $285.00 to $330.00 and gave the company a "buy" rating in a research note on Tuesday, July 14th. Finally, TD Cowen restated a "buy" rating on shares of Natera in a research report on Wednesday, July 15th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $267.83.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its stake in shares of Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock worth $2,944,800,000 after purchasing an additional 1,225,420 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Natera by 94.7% during the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company's stock valued at $1,140,026,000 after purchasing an additional 2,420,263 shares in the last quarter. State Street Corp lifted its holdings in Natera by 2.2% in the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company's stock worth $545,624,000 after purchasing an additional 72,087 shares during the period. Coatue Management LLC lifted its holdings in Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company's stock worth $603,270,000 after purchasing an additional 2,463,008 shares during the period. Finally, Geode Capital Management LLC grew its position in Natera by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 2,608,644 shares of the medical research company's stock valued at $596,078,000 after buying an additional 11,689 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.